Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review.

about

Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review.

Item

http://www.wikidata.org/entity/Q38915858

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Is surgery mandatory in locall ...... report and literature review.

@en

type

Item

label

Is surgery mandatory in locall ...... report and literature review.

@en

prefLabel

Is surgery mandatory in locall ...... report and literature review.

@en

P1476

Is surgery mandatory in locall ...... e report and literature review

@en

P2093

Alessandra Cassano

http://www.w3.org/2001/XMLSchema#string

Carlo Barone

http://www.w3.org/2001/XMLSchema#string

Carmela Di Dio

http://www.w3.org/2001/XMLSchema#string

Maurizio Martini

http://www.w3.org/2001/XMLSchema#string

Michela Quirino

http://www.w3.org/2001/XMLSchema#string

Riccardo Ricci

http://www.w3.org/2001/XMLSchema#string

Teresa Congedo

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?

Molecular pathobiology of gastrointestinal stromal sarcomas.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

P304

E4-E9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.21037/JGO.2016.12.02

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vincenzo Di Noia

Sabrina Rossi

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28280629

http://www.w3.org/2001/XMLSchema#string

P932

5334042

http://www.w3.org/2001/XMLSchema#string